New drug elacestrant aims to keep High-Risk breast cancer at bay
NCT ID NCT07242352
First seen Nov 21, 2025 · Last updated May 24, 2026 · Updated 21 times
Summary
This study tests if a new hormone therapy called elacestrant, taken for 5 years, can better prevent breast cancer from coming back compared to standard hormone therapy in people with high-risk HR+/HER2- early breast cancer. About 1,520 participants will receive either elacestrant (with or without another drug) or standard care. The goal is to see who stays cancer-free longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus
RECRUITINGMönchengladbach, North Rhine-Westphalia, 41061, Germany
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.